Table 2 Effect of CSF biomarkers and genetic risk scores on the diagnosis of PD.

From: Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease

 

Model 1

Model 2

Model 3

 

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

Age

1.01 (0.99–1.02)

0.132

1.01 (0.99–1.02)

0.194

1.01 (0.99–1.02)

0.052

Sex, Male

1.03 (0.72–1.48)

0.560

1.06 (0.72–1.54)

0.949

1.06 (0.72–1.54)

0.736

Education

0.94 (0.89–0.99)

0.016

0.94 (0.88–0.99)

0.041

0.94 (0.88–0.99)

0.027

GRS-AD

1.06 (0.82–1.37)

0.683

  

1.00 (0.76–1.30)

0.906

GRS-PD

2.36 (1.80–3.09)

<0.001

  

2.34 (1.75–3.12)

<0.001

Baseline αSyn

  

0.69 (0.53–0.89)

0.004

0.69 (0.53–0.89)

0.011

Baseline p-tau/Aβ42

  

0.99 (0.98–1.01)

0.245

0.99 (0.98–1.01)

0.229

  1. αSyn α-synuclein, Aβ42 42-residue amyloid-beta, AD Alzheimer’s disease, CSF Cerebrospinal fluid, GRS Genetic risk score, PD Parkinson’s disease.
  2. Data are presented as the results of a logistic regression model for the diagnosis of PD as a dependent variable using either GRS-AD, GRS-PD (model 1), CSF biomarkers (model 2), or both (model 3) as predictors in all subjects including healthy controls and the PD group. The covariates included age, sex, education, and the first four principal components.
  3. Significant P values are indicated in bold.
Back to article page